aAmerican College of Surgeons, Chicago, IL
bDepartment of Surgery, Loyola University Medical Center, Maywood, IL
cFeinberg School of Medicine, Northwestern University, Chicago, IL
dDepartment of Surgery, University of Texas Southwestern, Dallas, TX
eDepartment of Surgery, John Peter Smith Health Network, Fort Worth, TX
fDepartment of Breast Oncology, Moffitt Cancer Center, Tampa, FL
gDepartment of Surgery, University of Louisville, Louisville, KY
hDepartment of Surgery, University of Minnesota, Minneapolis, MN
iDepartment of Surgery, Boston Veterans Affairs Health Care System, Boston University, Boston, MA
jDepartment of Surgery, University of Washington, Seattle, WA
kDepartment of Surgery, University of California Los Angeles, Los Angeles, CA
Correspondence address: Therese M Duane, MD, MBA, FACS, Division of Trauma Critical Care and Emergency Surgery, John Peter Smith Health Network, 1200 S Main St, Fort Worth, TX 76104.
E-mail: [email protected]
Submitted September 27, 2016; accepted October 5, 2016.
Disclosure Information: Nothing to disclose.
Disclosures outside the scope of this work: Dr. Minei receives clinical trial grant support from Irrespet Corp. AtoxBio. Dr. Laronga receives compensation for lectures from Genomic Health Inc. and royalties from Up-To-Date. Dr. Jensen is a consultant and paid speaker for Ethicon. Dr. Fry receives honoraria from CareFusion for their Speaker’s Program, honoraria from Irrimax Corp. for consulting and Research Funding Prescient, and honoraria from Surgical Inc. for consultation. Dr. Itani is the site PI for a multi-institutional study for Sanofi-Pastuer and the ACS Research Committee Chair. Dr. Dellinger is on the Advisory Board for 3M, Melinta, and Therevance and a grant recipient from Motif for a clinical trial of iclaprim vs. vancomycin for treatment of skin and soft tissue infections. The remaining authors declare no conflicts.
Presented at the Surgical Infection Society, Palm Beach, FL, May 2016.
